Serum Lipid Profiles, Blood Glucose, and High-Sensitivity C-Reactive Protein Levels Among People Living with HIV Taking Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy at Jimma University Medical Center, Southwest Ethiopia, 2021.
Nuredin Chura WarituSuresh Kumar P NairBihonegn BirhanTesfaye AdugnaGesese Bogale AwgichewMohammed JemalPublished in: HIV/AIDS (Auckland, N.Z.) (2024)
When compared to ritonavir-boosted atazanavir-based regimens, dolutegravir had favorable lipid profiles and high-sensitivity C-reactive protein but unfavorable blood glucose levels. Therefore, baseline blood glucose, lipid profiles, and high-sensitivity C-reactive protein levels should be routinely measured in patients on these regimens.
Keyphrases
- blood glucose
- antiretroviral therapy
- hiv infected patients
- hiv infected
- glycemic control
- human immunodeficiency virus
- hiv positive
- hiv aids
- blood pressure
- fatty acid
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- patient reported outcomes
- adipose tissue
- hepatitis c virus
- skeletal muscle
- patient reported